Implants inserted in the posterior maxilla frequently need additional surgery for successful bone augmentation. One of the most common procedures for this is transalveolar sinus floor elevation. There are different protocols for this procedure, and there is controversy over the simultaneous application of grafting material upon elevating. In this prospective randomized clinical study in humans, a total of 49 transalveolar sinus floor elevations were performed in 49 different patients, divided into a control group (without graft, 25 patients) and a test group (with graft, 24 patients). The analyzed variables were obtained through digital orthopantomography on day 0 (day of surgery) and 18 months after surgery. These measurements showed a tendency towards greater vertical bone gain in the test group, but this was not statistically significant. Therefore, considering that sinus elevation and implant placement without the application of grafts is a successful treatment with fewer complications, a critical assessment of the need for these biomaterials is necessary.

BACKGROUND: Implant placement in the posterior maxilla is often complicated by the insufficient bone volume. While transalveolar sinus floor elevation (TSFE) has been proven as a predictable surgical procedure to increase the bone height in the posterior maxilla, questions in regard to the necessity of the bone grafting during the sinus lift and the question of whether TSFE could be performed when the residual bone height is below 5 mm are still debated. Furthermore, high-quality evidence comparing the clinical outcome of transalveolar sinus floor elevation with osteotome and modified sinus floor elevation with crestal non-cutting drills is limited.
METHODS: One hundred twenty adult patients who fit the inclusion criteria are being recruited from the Peking University Hospital of Stomatology First Clinical Division (Beijing, China). All patients are assigned to one of four groups according to a table of random numbers. Participants will receive (1) TSFE using osteotomes with bone grafting, (2) TSFE using osteotomes without bone grafting, (3) modified TSFE with bone grafting, or (4) modified TSFE without bone grafting. In a one-year follow-up period, implant survival rates, complications, implant stability, bone remodeling around the implant, and patient-reported outcome (visual analog scale for intraoperative discomfort and postoperative pain) will be observed and documented. The implant stability will be gauged by the resonance frequency analysis six times (at baseline and weeks 6, 8, 12, 16, and 26), and the bone remodeling will be observed and compared via radiographic examinations.
CONCLUSIONS: The result of the trial will potentially contribute to better decision making in atrophic posterior maxilla when implant placement is needed. Therefore, if the outcome is deemed favorable, the use of the modified TSFE would achieve an outcome equivalent to that of the traditional TSFE while introducing less trauma and postoperative discomforts. Separately, whether the bone graft procedure is necessary for the TSFE will also be discussed.
BACKGROUND: The study has been registered in ClinicalTrials.gov under the identifier number NCT03445039 . Registered on 26 February 2018.

To evaluate endo-sinus new bone formation and implant osseointegration after transalveolar sinus floor elevation (TSFE) and simultaneous implant placement without any grafting materials and to investigate the influence of implant surface modification on bone healing process under this circumstance.
Transalveolar sinus floor elevation and simultaneous implant placement were conducted bilaterally on 12 Labrador dogs. No grafting materials were used during surgery. Implants with two different surfaces (SLA and SLActive) were placed in a split-mouth design. The animals were sacrificed 4, 8 and 24 weeks after surgery for histological and histomorphometric assessments. Bone-to-implant contact (BIC%), alveolar bone height (ABH) and the percentages of mineralized bone (MB%) in the area of interest were analysed. The probing depth (PD) and bleeding on probing (BOP) were also assessed to describe peri-implant health conditions.
Sprouts of new bone in direct contact with implant surface were seen in the elevated area at every time point. Newly formed woven bone under sinus membrane was visible. SLActive implants exhibited favourable results compared with SLA implants regarding ABH at 4 weeks and BIC% at 4 and 8 weeks. Sites with BOP positive could be observed in both groups at any time point. No newly formed bone can be found on the implant apex with either SLA or SLActive surfaces at any time point.
Spontaneous new bone formation from the parent bone walls could be observed after TFE without any grafting materials. No clear evidence of bone formation from the Schneiderian membrane could be found. Even though there were trends for quicker bone response of SLActive implants, this study failed to show the absolute advantage of SLActive in achieving endo-sinus bone formation.

OBJECTIVE: The aim of this study was to assess the clinical success of dental implants placed in severely atrophic maxilla (residual bone height ≤4 mm) using transalveolar sinus floor elevation (TSFE) without grafting. Furthermore, the implant stability during the healing period was also evaluated.
METHODS: Twenty five generally healthy patients with 37 Straumann(®) Standard Plus SLA implants were included in the study. After a modified Summers TSFE without grafting was performed, the smooth collar was embedded 0.5-1 mm beneath the cortical bone level. Follow-ups were conducted at 12, 36, and 60 months after crown placement. Implant survival rate, resonance frequency analysis (RFA), and clinical and radiographic parameters were evaluated.
RESULTS: At 5-year follow-up, 35 implants fulfilled the survival criteria, representing a 5-year cumulative survival rate of 94.6% at implant level and 92% at subject level. The mean value of implant stability quotient (ISQ) ranged from 67.8 to 72.8, and the lowest values were reached at 4 weeks. No significant difference was found with the passage of time in modified plaque index (P = 0.92), pocket probing depth (P = 0.34), and modified bleeding index (P = 0.4). The average residual bone height was 2.81 mm (SD: 0.74 mm) in this study. The average crestal bone loss (CBL) significantly increased from 0.83 mm at 1-year examination to 1.47 mm at 3-year examination (P < 0.001). The average CBL remained stable at years 3 and 5 (1.47 vs. 1.54 mm, P = 0.083).
CONCLUSIONS: According to the current evidence, it is feasible to place cylindrical implants in severely atrophic maxilla. High survival rate could be achieved following TSFE without grafting at least within 5-year follow-up.